Dawn Sepulveda
Family Medicine · Boynton Beach, FLNPI 1013430701
Payments from drug & device makers
Across 245 payments — averaging $19.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$764
- Bayer$508
- Lilly USA, LLC$486
- Boehringer Ingelheim$438
- AstraZeneca$255
- Amgen$219
- plus $2K from 27 others
What the payments were for
- Food & beverage$4,854100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 40 | $764 |
| Bayer | 26 | $508 |
| Lilly USA, LLC | 25 | $486 |
| Boehringer Ingelheim | 21 | $438 |
| AstraZeneca | 12 | $255 |
| Amgen | 11 | $219 |
| Exact Sciences | 9 | $201 |
| Amarin Pharma, Inc. | 12 | $188 |
| GSK | 9 | $179 |
| Abbott | 7 | $168 |
| Pfizer | 7 | $163 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $128 |
| Esperion Therapeutics, Inc. | 6 | $103 |
| Novo Nordisk | 6 | $103 |
| Astellas Pharma US Inc | 4 | $98 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $90 |
| Alnylam Pharmaceuticals Inc. | 5 | $90 |
| Dexcom, Inc. | 4 | $87 |
| Biohaven Pharmaceuticals, Inc. | 4 | $84 |
| Novartis | 4 | $77 |
| Adlon Therapeutics L.p. | 4 | $58 |
| Johnson & Johnson | 2 | $57 |
| Jazz Pharmaceuticals Inc. | 3 | $50 |
| Otsuka America Pharmaceutical, Inc. | 2 | $45 |
| Eisai Inc. | 3 | $40 |
| Edwards Lifesciences | 1 | $31 |
| Inspire Medical Systems, Inc. | 1 | $29 |
| Corcept Therapeutics | 1 | $24 |
| Genentech USA, Inc. | 1 | $22 |
| Sanofi Pasteur Inc. | 1 | $21 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $19 |
| Merck | 1 | $16 |
| Antares Pharma, Inc. | 1 | $15 |
How this compares
$4,854 in reported general payments places this provider in the 85th percentile of 7,282 family medicine providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 12 | $13,949 |
| Rosuvastatin Calcium | 42 | $623 |
| Zolpidem Tartrate | 42 | $513 |
| Alprazolam | 111 | $465 |
| Methylprednisolone | 73 | $450 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 14 | $307 |
| Ipratropium Bromide | 13 | $306 |
| Pregabalin | 12 | $305 |
| Atorvastatin Calcium | 22 | $278 |
| Doxycycline Monohydrate | 22 | $226 |
| Lisinopril | 17 | $197 |
| Clonazepam | 21 | $181 |
| Gabapentin | 18 | $176 |
| Azithromycin | 44 | $170 |
| Temazepam | 27 | $141 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $486 | $13,94912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Boynton Beach
- Rasha YoussefBoynton Beach$7.4M
- Hugh ColemanDaytona Beach$115.5M
- Alexander WhiteDaytona Beach$69.7M
- Ronald SurowitzJupiter$38.3M
- Bruce RankinDeland$36.7M
- Keila HooverMiami$33.7M
- John NardandreaOcala$30.8M
- Jorge CasoMiami$22.6M
- Sharrell CooperPalm Coast$16.9M
- Christopher GallowayMelbourne$15.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.